Username

Password

Forgot Password?

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Joep Lange

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Disorders

Living Beings

HIV-1

Chemicals & Drugs

Procedures

Concepts & Ideas

Anatomy

CD4-Positive T-Lymphocytes

Sign-in to see full Profile

Network (preview)

Co-Publications
Name
54
de Wolf, Frank
54
Reiss, Peter
49
Goudsmit, Jaap
39
Jurriaans, Suzanne
38
Danner, Sven
36
Prins, Jan
35
Mulder, Jan
34
Miedema, Frank
34
Weverling, Gerrit Jan
33
Wit, Ferdinand
32
Hoetelmans, Richard
27
Cooper, David
26
Coutinho, Roel
26
Phanuphak, Praphan
24
Schuitemaker, Hanneke

Sign-in to see all Coauthors

Publications

TOP 3
Steingrover Radjin; Pogány Katalyn; Fernandez Garcia Evian; Jurriaans Suzanne; Brinkman Kees; Schuitemaker Hanneke; Miedema Frank; Lange Joep Ma; Prins Jan M
HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
Wit Ferdinand W N M; Kesselring Anouk M; Gras Luuk; Richter Clemens; van der Ende Marchina E; Brinkman Kees; Lange Joep M A; de Wolf Frank; Reiss Peter
Discontinuation of nevirapine because of hypersensitivity reactions in patients with prior treatment experience, compared with treatment-naive patients: the ATHENA cohort study.
Vermeulen Joost N; Prins Jan M; Bunnik Evelien; Hack C Erik; Jurriaans Suzanne; Miedema Frank; Lange Joep M A; Schuitemaker Hanneke
Intravenous immunoglobulin (IVIG) treatment for modulation of immune activation in human immunodeficiency virus type 1 infected therapy-naive individuals.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Joep Lange (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2008: Steingrover Radjin; Pogány Katalyn; Fernandez Garcia Evian; Jurriaans Suzanne; Brinkman Kees; Schuitemaker Hanneke; Miedema Frank; Lange Joep Ma; Prins Jan M
HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
AIDS (London, England) 2008;22(13):1583-8.
2008: Wit Ferdinand W N M; Kesselring Anouk M; Gras Luuk; Richter Clemens; van der Ende Marchina E; Brinkman Kees; Lange Joep M A; de Wolf Frank; Reiss Peter
Discontinuation of nevirapine because of hypersensitivity reactions in patients with prior treatment experience, compared with treatment-naive patients: the ATHENA cohort study.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2008;46(6):933-40.
2007: Vermeulen Joost N; Prins Jan M; Bunnik Evelien; Hack C Erik; Jurriaans Suzanne; Miedema Frank; Lange Joep M A; Schuitemaker Hanneke
Intravenous immunoglobulin (IVIG) treatment for modulation of immune activation in human immunodeficiency virus type 1 infected therapy-naive individuals.
AIDS research and human retroviruses 2007;23(11):1348-53.
2007: Lowe Selwyn H; van Leeuwen Elisabeth; Droste Jacqueline A H; van der Veen Fulco; Reiss Peter; Lange Joep M A; Burger David M; Repping Sjoerd; Prins Jan M
Semen quality and drug concentrations in seminal plasma of patients using a didanosine or didanosine plus tenofovir containing antiretroviral regimen.
Therapeutic drug monitoring 2007;29(5):566-70.
2007: Lowe Selwyn H; Hassink Elly A M; van Eck-Smit Berthe L F; Borleffs Jan C C; Lange Joep M A; Reiss Peter
Stavudine but not didanosine as part of HAART contributes to peripheral lipoatrophy: a substudy from the Antiretroviral Regimen Evaluation Study (ARES).
HIV clinical trials 2007;8(5):337-44.
2007: Autar Reshma Saskia; Wit Ferdinand W N M; Sankote Jongkol; Sutthichom Duanghathai; Kimenai Elly; Hassink Elly; Hill Andrew; Cooper David A; Phanuphak Praphan; Lange Joep M A; Burger David M; Ruxrungtham Kiat
Ketoconazole is inferior to ritonavir as an alternative booster for saquinavir in a once daily regimen in Thai HIV-1 infected patients.
AIDS (London, England) 2007;21(12):1535-9.
2007: Sankatsing Raaj R; Wit Ferdinand W; Pakker Nadine; Vyankandondera Joseph; Mmiro Francis; Okong Pius; Kastelein John J; Lange Joep M; Stroes Erik S; Reiss Peter
Effects of nevirapine, compared with lamivudine, on lipids and lipoproteins in HIV-1-uninfected newborns: the stopping infection from mother-to-child via breast-feeding in Africa lipid substudy.
The Journal of infectious diseases 2007;196(1):15-22.
2007: Gras Luuk; Kesselring Anouk M; Griffin James T; van Sighem Ard I; Fraser Christophe; Ghani Azra C; Miedema Frank; Reiss Peter; Lange Joep M A; de Wolf Frank;
CD4 cell counts of 800 cells/mm3 or greater after 7 years of highly active antiretroviral therapy are feasible in most patients starting with 350 cells/mm3 or greater.
Journal of acquired immune deficiency syndromes (1999) 2007;45(2):183-92.
2007: Vrouenraets Saskia M E; Wit Ferdinand W N M; van Tongeren Jacqueline; Lange Joep M A
Efavirenz: a review.
Expert opinion on pharmacotherapy 2007;8(6):851-71.
2007: Pogány Katalin; van Valkengoed Irene G M; Prins Jan M; Nieuwkerk Pythia T; van der Ende Ineke; Kauffmann Robbert H; Kroon Frank P; Verbon Annelies; Nievaard Marianne F; Lange Joep M A; Brinkman Kees
Effects of active treatment discontinuation in patients with a CD4+ T-cell nadir greater than 350 cells/mm3: 48-week Treatment Interruption in Early Starters Netherlands Study (TRIESTAN).
Journal of acquired immune deficiency syndromes (1999) 2007;44(4):395-400.
2007: Kerr Stephen J; Duncombe Chris; Avihingsanon Anchalee; Ananworanich Jintanat; Boyd Mark; Sopa Bunruan; Medtech B; Chuenyam Theshinee; Cooper David A; Lange Joep M A; Phanuphak Praphan; Ruxrungtham Kiat
Dyslipidemia in an Asian population after treatment for two years with protease inhibitor-containing regimens.
Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 2007;6(1):36-46.
2007: Scherpbier Henriëtte J; Bekker Vincent; Pajkrt Dasja; Jurriaans Suzanne; Lange Joep M A; Kuijpers Taco W
Once-daily highly active antiretroviral therapy for HIV-infected children: safety and efficacy of an efavirenz-containing regimen.
Pediatrics 2007;119(3):e705-15.
2007: Sow Papa S; Otieno Leander F; Bissagnene Emmanuel; Kityo Cissy; Bennink Ruurd; Clevenbergh Philippe; Wit Ferdinand W N M; Waalberg Esther; Rinke de Wit Tobias F; Lange Joep M;
Implementation of an antiretroviral access program for HIV-1-infected individuals in resource-limited settings: clinical results from 4 African countries.
Journal of acquired immune deficiency syndromes (1999) 2007;44(3):262-7.
2007: Sankatsing Sanjay U C; Cornelissen Marion; Kloosterboer Nico; Crommentuyn Kristel M L; Bosch Tessa M; Mul Frederik P; Jurriaans Suzanne; Huitema Alwin D R; Beijnen Jos H; Lange Joep M A; Prins Jan M; Schuitemaker Hanneke
Antiviral activity of HIV type 1 protease inhibitors nelfinavir and indinavir in vivo is not influenced by P-glycoprotein activity on CD4+ T cells.
AIDS research and human retroviruses 2007;23(1):19-27.
2007: van Leth Frank; Wit Ferdinand W; Lange Joep M
Methodological standards in non-inferiority AIDS trials: moving from adherence to compliance: response.
BMC medical research methodology 2007;7():14.
2006: Lowe Selwyn H; Wensing Annemarie M J; Droste Jacqueline A H; ten Kate Reinier W; Jurriaans Suzanne; Burger David M; Borleffs Jan C C; Lange Joep M A; Prins Jan M
No virological failure in semen during properly suppressive antiretroviral therapy despite subtherapeutic local drug concentrations.
HIV clinical trials 2006;7(6):285-90.
2006: Derdelinckx Inge; Wainberg Mark A; Lange Joep M A; Hill Andrew; Halima Yasmin; Boucher Charles A B
Criteria for drugs used in pre-exposure prophylaxis trials against HIV infection.
PLoS medicine 2006;3(11):e454.
2006: Boyd Mark A; Dixit Narendra M; Siangphoe Umaporn; Buss Neil E; Salgo Miklos P; Lange Joep M A; Phanuphak Praphan; Cooper David A; Perelson Alan S; Ruxrungtham Kiat
Viral decay dynamics in HIV-infected patients receiving ritonavir-boosted saquinavir and efavirenz with or without enfuvirtide: a randomized, controlled trial (HIV-NAT 012).
The Journal of infectious diseases 2006;194(9):1319-22.
2006: Clevenbergh P; Van der Borght S F M; van Cranenburgh K; Janssens V; Kitenge Lubangi C; Gahimbaza L; Lange J M A; Rinke de Wit T F; Rijckborst H
Database-supported teleconferencing: an additional clinical mentoring tool to assist a multinational company HIV/AIDS treatment program in Africa.
HIV clinical trials 2006;7(5):255-62.
2006: van Leth F; Hall D B; Lange J M A; Reiss P
Plasma lipid concentrations after 1.5 years of exposure to nevirapine or efavirenz together with stavudine and lamivudine.
HIV medicine 2006;7(6):347-50.
2006: Boyd Mark A; Carr Andrew; Ruxrungtham Kiat; Srasuebkul Preeyaporn; Bien Darl; Law Matthew; Wangsuphachart Somjai; Krisanachinda Anchali; Lerdlum Sakalaya; Lange Joep M A; Phanuphak Praphan; Cooper David A; Reiss Peter
Changes in body composition and mitochondrial nucleic acid content in patients switched from failed nucleoside analogue therapy to ritonavir-boosted indinavir and efavirenz.
The Journal of infectious diseases 2006;194(5):642-50.
2006: Van der Borght Stefaan; Rinke de Wit Tobias F; Janssens Vincent; Schim van der Loeff Maarten F; Rijckborst Henk; Lange Joep M A
HAART for the HIV-infected employees of large companies in Africa.
Lancet 2006;368(9534):547-50.
2006: Boyd Mark A; Siangphoe Umaporn; Ruxrungtham Kiat; Reiss Peter; Mahanontharit Apicha; Lange Joep M A; Phanuphak Praphan; Cooper David A; Burger David M
The use of pharmacokinetically guided indinavir dose reductions in the management of indinavir-associated renal toxicity.
The Journal of antimicrobial chemotherapy 2006;57(6):1161-7.
2006: Boyd Mark A; Srasuebkul Preeyaporn; Ruxrungtham Kiat; Mackenzie Peter I; Uchaipichat Verawan; Stek Michael; Lange Joep M A; Phanuphak Praphan; Cooper David A; Udomuksorn Wandee; Miners John O
Relationship between hyperbilirubinaemia and UDP-glucuronosyltransferase 1A1 (UGT1A1) polymorphism in adult HIV-infected Thai patients treated with indinavir.
Pharmacogenetics and genomics 2006;16(5):321-9.
2006: Leth F Van; Kappelhoff B S; Johnson D; Losso M H; Boron-Kaczmarska A; Saag M S; Livrozet J-M; Hall D B; Leith J; Huitema A D R; Wit F W; Beijnen J H; Lange J M A;
Pharmacokinetic parameters of nevirapine and efavirenz in relation to antiretroviral efficacy.
AIDS research and human retroviruses 2006;22(3):232-9.
2006: Scherpbier Henriëtte J; Bekker Vincent; van Leth Frank; Jurriaans Suzanne; Lange Joep M A; Kuijpers Taco W
Long-term experience with combination antiretroviral therapy that contains nelfinavir for up to 7 years in a pediatric cohort.
Pediatrics 2006;117(3):e528-36.
2006: Bekker Vincent; Scherpbier Henriëtte J; Steingrover Radjin; Jurriaans Suzanne; Lange Joep M A; Wolthers Katja C; Kuijpers Taco W
Viral dynamics after starting first-line HAART in HIV-1-infected children.
AIDS (London, England) 2006;20(4):517-23.
2006: Jansen Christine A; Piriou Erwan; De Cuyper Iris M; van Dort Karel; Lange Joep M A; Miedema Frank; van Baarle Debbie
Long-term highly active antiretroviral therapy in chronic HIV-1 infection: evidence for reconstitution of antiviral immunity.
Antiviral therapy 2006;11(1):105-16.
2005: Vrisekoop Nienke; Sankatsing Sanjay U C; Jansen Christine A; Roos Marijke Th L; Otto Sigrid A; Schuitemaker Hanneke; Lange Joep M A; Prins Jan M; Miedema Frank
Short communication: No detrimental immunological effects of mycophenolate mofetil and HAART in treatment-naive acute and chronic HIV-1-infected patients.
AIDS research and human retroviruses 2005;21(12):991-6.
2005: Pogány K; Zaaijer H L; Prins J M; Wit F W; Lange J M A; Beld M G H M
Occult hepatitis B virus infection before and 1 year after start of HAART in HIV type 1-positive patients.
AIDS research and human retroviruses 2005;21(11):922-6.
2005: Boyd M A; Siangphoe U; Ruxrungtham K; Duncombe C J; Stek M; Lange J M A; Cooper D A; Phanuphak P
Indinavir/ritonavir 800/100 mg bid and efavirenz 600 mg qd in patients failing treatment with combination nucleoside reverse transcriptase inhibitors: 96-week outcomes of HIV-NAT 009.
HIV medicine 2005;6(6):410-20.
2005: Casula Miriam; Weverling Gerrit Jan; Wit Ferdinand W; Timmermans Eveline C; Stek Michael; Lange Joep M; Reiss Peter
Mitochondrial DNA and RNA increase in peripheral blood mononuclear cells from HIV-1-infected patients randomized to receive stavudine-containing or stavudine-sparing combination therapy.
The Journal of infectious diseases 2005;192(10):1794-800.
2005: Leroy Valériane; Sakarovitch Charlotte; Cortina-Borja Mario; McIntyre James; Coovadia Hoosen; Dabis Francois; Newell Marie-Louise; Saba J; Gray G; Ndugwa Ch; Kilewo Ch; Massawe A; Kituuka P; Okong P; Grulich A; von Briesen H; Goudsmit J; Biberfeld G; Haverkamp G; Weverling G J; Lange J M A;
Is there a difference in the efficacy of peripartum antiretroviral regimens in reducing mother-to-child transmission of HIV in Africa?
AIDS (London, England) 2005;19(16):1865-75.
2005: Autar Reshma Saskia; Boffito Marta; Hassink Elly; Wit Ferdinand W N M; Ananworanich Jintanat; Siangphoe Umaporn; Pozniak Anton; Cooper David A; Phanuphak Praphan; Lange Joep M A; Ruxrungtham Kiat; Burger David M
Interindividual variability of once-daily ritonavir boosted saquinavir pharmacokinetics in Thai and UK patients.
The Journal of antimicrobial chemotherapy 2005;56(5):908-13.
2005: van Leth Frank; Prins Jan M; Lange Joep M A; Geerlings Suzanne E
Protease inhibitors and non-nucleoside reverse transcriptase inhibitors have a comparable effect on the CD4 cell change after switching to tenofovir-based regimens.
AIDS (London, England) 2005;19(15):1722-3.
2005: Kappelhoff Bregt S; Huitema Alwin D R; van Leth Frank; Robinson Patrick A; MacGregor Thomas R; Lange Joep M A; Beijnen Jos H;
Pharmacokinetics of nevirapine: once-daily versus twice-daily dosing in the 2NN study.
HIV clinical trials 2005;6(5):254-61.
2005: Lowe S H; Wensing A M J; Hassink E A M; ten Kate R W; Richter C; Schreij G; Koopmans P P; Juttmann J R; van der Tweel I; Lange J M A; Borleffs J C C
Comparison of two once-daily regimens with a regimen consisting of nelfinavir, didanosine, and stavudine in antiretroviral therapy-naïve adults: 48-week results from the Antiretroviral Regimen Evaluation Study (ARES).
HIV clinical trials 2005;6(5):235-45.
2005: Lange Joep M A
We must not let protestors derail trials of pre-exposure prophylaxis for HIV.
PLoS medicine 2005;2(9):e248.
2005: Piriou Erwan; Jansen Christine A; van Dort Karel; De Cuyper Iris; Nanlohy Nening M; Lange Joep M A; van Oers Marinus H J; Miedema Frank; van Baarle Debbie
Reconstitution of EBV latent but not lytic antigen-specific CD4+ and CD8+ T cells after HIV treatment with highly active antiretroviral therapy.
Journal of immunology (Baltimore, Md. : 1950) 2005;175(3):2010-7.
2005: Jansen Christine A; De Cuyper Iris M; Steingrover Radjin; Jurriaans Suzanne; Sankatsing Sanjay U C; Prins Jan M; Lange Joep M A; van Baarle Debbie; Miedema Frank
Analysis of the effect of highly active antiretroviral therapy during acute HIV-1 infection on HIV-specific CD4 T cell functions.
AIDS (London, England) 2005;19(11):1145-54.
2005: Bekker Vincent; Bronke Corine; Scherpbier Henriëtte J; Weel Jan F; Jurriaans Suzanne; Wertheim-van Dillen Pauline M E; van Leth Frank; Lange Joep M A; Tesselaar Kiki; van Baarle Debbie; Kuijpers Taco W
Cytomegalovirus rather than HIV triggers the outgrowth of effector CD8+CD45RA+CD27- T cells in HIV-1-infected children.
AIDS (London, England) 2005;19(10):1025-34.
2005: van Leth F; Andrews S; Grinsztejn B; Wilkins E; Lazanas M K; Lange J M A; Montaner J;
The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART.
AIDS (London, England) 2005;19(5):463-71.
2005: van Leth Frank; Huisamen Casper B; Badaro Roberto; Vandercam Bernard; de Wet Joss; Montaner Julio S G; Hall David B; Wit Ferdinand W N M; Lange Joep M A;
Plasma HIV-1 RNA decline within the first two weeks of treatment is comparable for nevirapine, efavirenz, or both drugs combined and is not predictive of long-term virologic efficacy: A 2NN substudy.
Journal of acquired immune deficiency syndromes (1999) 2005;38(3):296-300.
2005: Van der Bij Akke K; Kloosterboer Nico; Prins Maria; Boeser-Nunnink Brigitte; Geskus Ronald B; Lange Joep M A; Coutinho Roel A; Schuitemaker Hanneke
GB virus C coinfection and HIV-1 disease progression: The Amsterdam Cohort Study.
The Journal of infectious diseases 2005;191(5):678-85.
2005: Duncombe Chris; Kerr Stephen J; Ruxrungtham Kiat; Dore Gregory J; Law Matthew G; Emery Sean; Lange Joep M; Phanuphak Praphan; Cooper David A
HIV disease progression in a patient cohort treated via a clinical research network in a resource limited setting.
AIDS (London, England) 2005;19(2):169-78.
2005: Autar Reshma S; Wit Ferdinand W N M; Sankote Jongkol; Mahanontharit Apicha; Anekthananon Thanomsak; Mootsikapun Piroon; Sujaikaew Khanjtta; Cooper David A; Lange Joep M A; Phanuphak Praphan; Ruxrungtham Kiat; Burger David M
Nevirapine plasma concentrations and concomitant use of rifampin in patients coinfected with HIV-1 and tuberculosis.
Antiviral therapy 2005;10(8):937-43.
2005: Kappelhoff Bregt S; van Leth Frank; Robinson Patrick A; MacGregor Thomas R; Baraldi Ezio; Montella Francesco; Uip David E; Thompson Melanie A; Russell Darren B; Lange Joep M A; Beijnen Jos H; Huitema Alwin D R;
Are adverse events of nevirapine and efavirenz related to plasma concentrations?
Antiviral therapy 2005;10(4):489-98.
2004: Lowe S H; Prins J M; Lange J M A
Antiretroviral therapy in previously untreated adults infected with the human immunodeficiency virus type I: established and potential determinants of virological outcome.
The Netherlands journal of medicine 2004;62(11):424-40.
2004: Hazenberg Mette D; Otto Sigrid A; van Rossum Annemarie M C; Scherpbier Henriëtte J; de Groot Ronald; Kuijpers Taco W; Lange Joep M A; Hamann Dörte; de Boer Rob J; Borghans José A M; Miedema Frank
Establishment of the CD4+ T-cell pool in healthy children and untreated children infected with HIV-1.
Blood 2004;104(12):3513-9.
2004: Baldwin Chris E; Sanders Rogier W; Deng Yiqun; Jurriaans Suzanne; Lange Joep M; Lu Min; Berkhout Ben
Emergence of a drug-dependent human immunodeficiency virus type 1 variant during therapy with the T20 fusion inhibitor.
Journal of virology 2004;78(22):12428-37.
2004: Safreed-Harmon Kelly; Cooper David A; Lange Joep M A; Duncombe Chris; Phanuphak Praphan
The HIV Netherlands Australia Thailand research collaboration: lessons from 7 years of clinical research.
AIDS (London, England) 2004;18(15):1971-8.
2004: van Leth Frank; Conway Brian; Laplumé Hector; Martin Des; Fisher Martin; Jelaska Ante; Wit Ferdinand W; Lange Joep M A;
Quality of life in patients treated with first-line antiretroviral therapy containing nevirapine and/or efavirenz.
Antiviral therapy 2004;9(5):721-8.
2004: van Leth Frank; Phanuphak Prahpan; Stroes Erik; Gazzard Brian; Cahn Pedro; Raffi François; Wood Robin; Bloch Mark; Katlama Christine; Kastelein John J P; Schechter Mauro; Murphy Robert L; Horban Andrzej; Hall David B; Lange Joep M A; Reiss Peter
Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1.
PLoS medicine 2004;1(1):e19.
2004: Nellen Jeannine F J B; Schillevoort Igor; Wit Ferdinand W N M; Bergshoeff Alina S; Godfried Mieke H; Boer Kees; Lange Joep M A; Burger David M; Prins Jan M
Nelfinavir plasma concentrations are low during pregnancy.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2004;39(5):736-40.
2004: Sankatsing Sanjay U C; Jurriaans Suzanne; van Swieten Peter; van Leth Frank; Cornelissen Marion; Miedema Frank; Lange Joep M A; Schuitemaker Hanneke; Prins Jan M
Highly active antiretroviral therapy with or without mycophenolate mofetil in treatment-naive HIV-1 patients.
AIDS (London, England) 2004;18(14):1925-31.
2004: Nellen Jeannine F; Wit Ferdinand W; De Wolf Frank; Jurriaans Suzanne; Lange Joep M; Prins Jan M
Virologic and immunologic response to highly active antiretroviral therapy in indigenous and nonindigenous HIV-1-infected patients in the Netherlands.
Journal of acquired immune deficiency syndromes (1999) 2004;36(4):943-50.
2004: van der Valk Marc; Allick Gideon; Weverling Gerrit Jan; Romijn Johannes A; Ackermans Mariette T; Lange Joep M A; van Eck-Smit Berthe L F; van Kuijk Cornelis; Endert Erik; Sauerwein Hans P; Reiss Peter
Markedly diminished lipolysis and partial restoration of glucose metabolism, without changes in fat distribution after extended discontinuation of protease inhibitors in severe lipodystrophic human immunodeficient virus-1-infected patients.
The Journal of clinical endocrinology and metabolism 2004;89(7):3554-60.
2004: Gayle Helene; Lange Joep M A
Seizing the opportunity to capitalise on the growing access to HIV treatment to expand HIV prevention.
Lancet 2004;364(9428):6-8.
2004: Cooper David A; Lange Joep M A
Peptide inhibitors of virus-cell fusion: enfuvirtide as a case study in clinical discovery and development.
The Lancet infectious diseases 2004;4(7):426-36.
2004: Lowe Selwyn H; Sankatsing Sanjay U C; Repping Sjoerd; van der Veen Fulco; Reiss Peter; Lange Joep M A; Prins Jan M
Is the male genital tract really a sanctuary site for HIV? Arguments that it is not.
AIDS (London, England) 2004;18(10):1353-62.
2004: Lange Joep M A; Perriens Jos; Kuritzkes Dan; Zewdie Debrework
What policymakers should know about drug resistance and adherence in the context of scaling-up treatment of HIV infection.
AIDS (London, England) 2004;18 Suppl 3():S69-74.
2004: Lange Joep M A; Thaineua Vallop
Access for all?
Science (New York, N.Y.) 2004;304(5679):1875.
2004: Ungsedhapand Chaiwat; Srasuebkul Preeyaporn; Cardiello Peter; Ruxrungtham Kiat; Ratanasuwan Winai; Kroon Eugene D M B; Tongtalung Metta; Juengprasert Nittaya; Ubolyam Sasiwimol; Siangphoe Umaporn; Emery Sean; Lange Joep M A; Cooper David A; Phanuphak Praphan;
Three-year durability of dual-nucleoside versus triple-nucleoside therapy in a Thai population with HIV infection.
Journal of acquired immune deficiency syndromes (1999) 2004;36(2):693-701.
2004: Law W Phillip; Duncombe Chris J; Mahanontharit Apicha; Boyd Mark A; Ruxrungtham Kiat; Lange Joep M A; Phanuphak Praphan; Cooper David A; Dore Gregory J
Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohort.
AIDS (London, England) 2004;18(8):1169-77.
2004: van Leth F; Phanuphak P; Ruxrungtham K; Baraldi E; Miller S; Gazzard B; Cahn P; Lalloo U G; van der Westhuizen I P; Malan D R; Johnson M A; Santos B R; Mulcahy F; Wood R; Levi G C; Reboredo G; Squires K; Cassetti I; Petit D; Raffi F; Katlama C; Murphy R L; Horban A; Dam J P; Hassink E; van Leeuwen R; Robinson P; Wit F W; Lange J M A;
Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study.
Lancet 2004;363(9417):1253-63.
2004: Sankatsing Sanjay U C; Beijnen Jos H; Schinkel Alfred H; Lange Joep M A; Prins Jan M
P glycoprotein in human immunodeficiency virus type 1 infection and therapy.
Antimicrobial agents and chemotherapy 2004;48(4):1073-81.
2004: Blanckenberg Daniel H; Wood Robin; Horban Andrzej; Beniowski Marek; Boron-Kaczmarska Anna; Trocha Hanna; Halota Waldemar; Schmidt Reinhold E; Fatkenheuer G; Jessen Heiko; Lange Joep M A;
Evaluation of nevirapine and/or hydroxyurea with nucleoside reverse transcriptase inhibitors in treatment-naive HIV-1-infected subjects.
AIDS (London, England) 2004;18(4):631-40.
2004: van Leth F; Wit F W N M; Reiss P; Schattenkerk J K M E; van der Ende M E; Schneider M M E; Mulder J W; Frissen P H J; de Wolf F; Lange J M A
Differential CD4 T-cell response in HIV-1-infected patients using protease inhibitor-based or nevirapine-based highly active antiretroviral therapy.
HIV medicine 2004;5(2):74-81.
2004: Reiss P; Casula M; de Ronde A; Weverling G J; Goudsmit J; Lange J M A
Greater and more rapid depletion of mitochondrial DNA in blood of patients treated with dual (zidovudine+didanosine or zidovudine+zalcitabine) vs. single (zidovudine) nucleoside reverse transcriptase inhibitors.
HIV medicine 2004;5(1):11-4.
2004: Sankatsing Sanjay U C; Hoggard Patrick G; Huitema Alwin D R; Sparidans Rolf W; Kewn Stephen; Crommentuyn Kristel M L; Lange Joep M A; Beijnen Jos H; Back David J; Prins Jan M
Effect of mycophenolate mofetil on the pharmacokinetics of antiretroviral drugs and on intracellular nucleoside triphosphate pools.
Clinical pharmacokinetics 2004;43(12):823-32.
2003: Sankatsing Sanjay U C; Weverling Gerrit J; Peeters Monika; van't Klooster Gerben; Gruzdev Boris; Rakhmanova Aza; Danner Sven A; Jurriaans Suzanne; Prins Jan M; Lange Joep M A
TMC125 exerts similar initial antiviral potency as a five-drug, triple class antiretroviral regimen.
AIDS (London, England) 2003;17(18):2623-7.
2003: Boyd Mark A; Aarnoutse Rob E; Ruxrungtham Kiat; Stek Michael; van Heeswijk Rolf P G; Lange Joep M A; Cooper David A; Phanuphak Praphan; Burger David M
Pharmacokinetics of indinavir/ritonavir (800/100 mg) in combination with efavirenz (600 mg) in HIV-1-infected subjects.
Journal of acquired immune deficiency syndromes (1999) 2003;34(2):134-9.
2003: van Sighem Ard I; van de Wiel Mark A; Ghani Azra C; Jambroes Mariëlle; Reiss Peter; Gyssens Inge C; Brinkman Kees; Lange Joep M A; de Wolf Frank;
Mortality and progression to AIDS after starting highly active antiretroviral therapy.
AIDS (London, England) 2003;17(15):2227-36.
2003: Law W Phillip; Dore Gregory J; Duncombe Chris J; Mahanontharit Apicha; Boyd Mark A; Ruxrungtham Kiat; Lange Joep M A; Phanuphak Praphan; Cooper David A
Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996-2001.
AIDS (London, England) 2003;17(15):2191-9.
2003: Lange Joep M A
Efficacy and durability of nevirapine in antiretroviral drug näive patients.
Journal of acquired immune deficiency syndromes (1999) 2003;34 Suppl 1():S40-52.
2003: van Leth Frank; Lange Joep M A
Use of composite end points to measure clinical events.
JAMA : the journal of the American Medical Association 2003;290(11):1456-7; author reply 1457.
2003: Hazenberg Mette D; Otto Sigrid A; van Benthem Birgit H B; Roos Marijke Th L; Coutinho Roel A; Lange Joep M A; Hamann Dörte; Prins Maria; Miedema Frank
Persistent immune activation in HIV-1 infection is associated with progression to AIDS.
AIDS (London, England) 2003;17(13):1881-8.
2003: Cardiello Peter G; Samor Tarika; Burger David; Hoetelmans Richard; Mahanontharit Apicha; Ruxrungtham Kiat; Lange Joep M; Cooper David A; Phanuphak Praphan
Pharmacokinetics of lower doses of saquinavir soft-gel caps (800 and 1200 mg twice daily) boosted with itraconazole in HIV-1-positive patients.
Antiviral therapy 2003;8(3):245-9.
2003: van Leeuwen Remko; Katlama Christine; Murphy Robert L; Squires Kathleen; Gatell José; Horban Andrej; Clotet Bonaventura; Staszewski Shlomo; van Eeden Arne; Clumeck Nathan; Moroni Mauro; Pavia Andrew T; Schmidt Reinhold E; Gonzalez-Lahoz Juan; Montaner Julio; Antunes Francisco; Gulick Robert; Bánhegyi Dénes; van der Valk Marc; Reiss Peter; van Weert Liesbeth; van Leth Frank; Johnson Victoria A; Sommadossi Jean-Pierre; Lange Joep M
A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients.
AIDS (London, England) 2003;17(7):987-99.
2003: Sankatsing Sanjay U C; van Praag Rieneke M E; van Rij Ronald P; Rientsma Ronald; Jurriaans Suzanne; Lange Joep M A; Prins Jan M; Schuitemaker Hanneke
Dynamics of the pool of infected resting CD4 HLA-DR- T lymphocytes in patients who started a triple class five-drug antiretroviral regimen during primary HIV-1 infection.
Antiviral therapy 2003;8(2):137-42.
2003: Koks Cees H W; Huitema Alwin D R; Kroon Eugene D M B; Chuenyam Theshinee; Sparidans Rolf W; Lange Joep M A; Beijnen Jos H
Population pharmacokinetics of itraconazole in Thai HIV-1-infected persons.
Therapeutic drug monitoring 2003;25(2):229-33.
2003: Cardiello Peter G; Monhaphol Tarkika; Mahanontharit Apicha; van Heeswijk Rolf P; Burger David; Hill Andrew; Ruxrungtham Kiat; Lange Joep M; Cooper David A; Phanuphak Praphan
Pharmacokinetics of once-daily saquinavir hard-gelatin capsules and saquinavir soft-gelatin capsules boosted with ritonavir in HIV-1-infected subjects.
Journal of acquired immune deficiency syndromes (1999) 2003;32(4):375-9.
2003: Bogaards Johannes A; Weverling Gerrit Jan; Geskus Ronald B; Miedema Frank; Lange Joep M A; Bossuyt Patrick M M; Goudsmit Jaap
Low versus high CD4 cell count as starting point for introduction of antiretroviral treatment in resource-poor settings: a scenario-based analysis.
Antiviral therapy 2003;8(1):43-50.
2003: Burger David M; Hugen Patricia W H; Aarnoutse Rob E; Hoetelmans Richard M W; Jambroes Marielle; Nieuwkerk Pythia T; Schreij Gerrit; Schneider Margriet M E; van der Ende Marchina E; Lange Joep M A;
Treatment failure of nelfinavir-containing triple therapy can largely be explained by low nelfinavir plasma concentrations.
Therapeutic drug monitoring 2003;25(1):73-80.
2003: Schwartländer Bernhard; Lange Joep M A
Time to move on HIV/AIDS treatment and care.
IAPAC monthly 2003;9(1):6-7.
2002: Wit Ferdinand W N M; van Rij Ronald P; Weverling Gerrit Jan; Lange Joep M A; Schuitemaker Hanneke
CC chemokine receptor 5 delta32 and CC chemokine receptor 2 64I polymorphisms do not influence the virologic and immunologic response to antiretroviral combination therapy in human immunodeficiency virus type 1-infected patients.
The Journal of infectious diseases 2002;186(12):1726-32.
2002: Boelaert Johan R; Dom Geneviève M; Huitema Alwin D; Beijnen Jos H; Lange Joep M
The boosting of didanosine by allopurinol permits a halving of the didanosine dosage.
AIDS (London, England) 2002;16(16):2221-3.
2002: Lange Joep M A; van der Waals Fransje W
Prioritising access to antiretroviral therapy in resource-poor settings.
Journal of HIV therapy 2002;7(3):59-62.
2002: Sankatsing Sanjay U C; Droste Jackie; Burger David; Van Praag Rieneke M E; Jurriaans Suzanne; Lange Joep M A; Prins Jan M
Limited penetration of lopinavir into seminal plasma of HIV-1-infected men.
AIDS (London, England) 2002;16(12):1698-700.
2002: van Heeswijk Rolf P G; Scherpbier Henriëtte J; de Koning Linda A; Heymans Hugo S A; Lange Joep M A; Beijnen Jos H; Hoetelmans Richard M W
The pharmacokinetics of nelfinavir in HIV-1-infected children.
Therapeutic drug monitoring 2002;24(4):487-91.
2002: Lowe Selwyn H; Prins Jan M; van der Lelie Johannes; Lange Joep M A
Does highly active antiretroviral therapy induce sickle cell crises?
AIDS (London, England) 2002;16(11):1572-4.
2002: Blank B S N; Meenhorst P L; Pauw W; Mulder J W; van Dijk W C; Smits P H M; Roeles F; Middeldorp J M; Lange J M A
Detection of late pp67-mRNA by NASBA in peripheral blood for the diagnosis of human cytomegalovirus disease in AIDS patients.
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 2002;25(1):29-38.
2002: Wit Ferdinand W N M; Weverling Gerrit Jan; Weel Jan; Jurriaans Suzanne; Lange Joep M A
Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy.
The Journal of infectious diseases 2002;186(1):23-31.
2002: Hazenberg Mette D; Otto Sigrid A; Wit Ferdinand W N M; Lange Joep M A; Hamann Dörte; Miedema Frank
Discordant responses during antiretroviral therapy: role of immune activation and T cell redistribution rather than true CD4 T cell loss.
AIDS (London, England) 2002;16(9):1287-9.
2002: Dieleman Jeanne P; Sturkenboom Miriam C J M; Wit Ferdinand W; Jambroes Marielle; Mulder Jan-Willem; Ten Veen Jacob H; Juttmann Job; Stricker Bruno H C; Lange Joep M A; Van Der Ende Marchina E;
Low risk of treatment failure after substitution of nevirapine for protease inhibitors among human immunodeficiency virus-infected patients with virus suppression.
The Journal of infectious diseases 2002;185(9):1261-8.
2002: Lange Joep M A; van Leeuwen Remko
Antiretroviral therapy and resistance to antiretroviral drugs.
Ethiopian medical journal 2002;40 Suppl 1():51-75.
2002: Cardiello Peter G; van Heeswijk Rolf P; Hassink Elly A; Srasuebkul Preeyaporn; Mahanontharit Apicha; Samor Tarika M; Worarien Wassana; Beijnen Jos H; Hoetelmans Richard M; Ruxrungtham Kiat; Cooper David A; Lange Joep M; Phanuphak Praphan
Simplifying protease inhibitor therapy with once-daily dosing of saquinavir soft-gelatin capsules/ritonavir (1600/100 mg): HIVNAT 001.3 study.
Journal of acquired immune deficiency syndromes (1999) 2002;29(5):464-70.
2002: Rongkavilit Chokechai; van Heeswijk Rolf P G; Limpongsanurak Sompop; Thaithumyanon Pimolrat; Boonrod Chantana; Hassink Elly A M; Srigritsanapol Aeumporn; Chuenyam Theshinee; Ubolyam Sasiwimol; Hoetelmans Richard M W; Ruxrungtham Kiat; Lange Joep M A; Cooper David A; Phanuphak Praphan
Dose-escalating study of the safety and pharmacokinetics of nelfinavir in HIV-exposed neonates.
Journal of acquired immune deficiency syndromes (1999) 2002;29(5):455-63.
2002: Kostense Stefan; Otto Sigrid A; Knol Gerlinde J; Manting Erik H; Nanlohy Nening M; Jansen Christine; Lange Joep M A; van Oers Marinus H J; Miedema Frank; van Baarle Debbie
Functional restoration of human immunodeficiency virus and Epstein-Barr virus-specific CD8(+) T cells during highly active antiretroviral therapy is associated with an increase in CD4(+) T cells.
European journal of immunology 2002;32(4):1080-9.
2002: van Rij Ronald P; van Praag Rieneke M E; Prins Jan M; Rientsma Ronald; Jurriaans Suzanne; Lange Joep M A; Schuitemaker Hanneke
Persistence of viral HLA-DR- CD4 T-cell reservoir during prolonged treatment of HIV-1 infection with a five-drug regimen.
Antiviral therapy 2002;7(1):37-41.
2002: Goudsmit Jaap; Bogaards Johannes A; Jurriaans Suzanne; Schuitemaker Hanneke; Lange Joep M A; Coutinho Roel A; Weverling Gerrit Jan
Naturally HIV-1 seroconverters with lowest viral load have best prognosis, but in time lose control of viraemia.
AIDS (London, England) 2002;16(5):791-3.
2002: Dieleman Jeanne P; Jambroes Marielle; Gyssens Inge C; Sturkenboom Miriam C J M; Stricker Bruno H Ch; Mulder Wilhelmina M C; de Wolf Frank; Weverling Gerrit-Jan; Lange Joep M A; Reiss Peter; Brinkman Kees;
Determinants of recurrent toxicity-driven switches of highly active antiretroviral therapy. The ATHENA cohort.
AIDS (London, England) 2002;16(5):737-45.
2002: van Praag Rieneke M E; Wit Ferdinand W N M; Jurriaans Suzanne; de Wolf Frank; Prins Jan M; Lange Joep M A
Improved long-term suppression of HIV-1 replication with a triple-class multidrug regimen compared with standard of care antiretroviral therapy.
AIDS (London, England) 2002;16(5):719-25.
2002: van Rij Ronald P; Visser Janny A; van Praag Rieneke M E; Rientsma Ronald; Prins Jan M; Lange Joep M A; Schuitemaker Hanneke
Both R5 and X4 human immunodeficiency virus type 1 variants persist during prolonged therapy with five antiretroviral drugs.
Journal of virology 2002;76(6):3054-8.
2002: van Praag Rieneke M E; van Weert Elisabeth C M; van Heeswijk Rolf P G; Zhou Xiao-Jian; Sommadossi Jean-Pierre; Jurriaans Suzanne; Lange Joep M A; Hoetelmans Richard M W; Prins Jan M
Stable concentrations of zidovudine, stavudine, lamivudine, abacavir, and nevirapine in serum and cerebrospinal fluid during 2 years of therapy.
Antimicrobial agents and chemotherapy 2002;46(3):896-9.
2001: van Heeswijk R P; Veldkamp A; Mulder J W; Meenhorst P L; Lange J M; Beijnen J H; Hoetelmans R M
Combination of protease inhibitors for the treatment of HIV-1-infected patients: a review of pharmacokinetics and clinical experience.
Antiviral therapy 2001;6(4):201-29.
2001: Veldkamp A I; van Heeswijk R P; Mulder J W; Meenhorst P L; Hoetelmans R M; Lange J M; Beijnen J H
Limited sampling strategies for the estimation of the systemic exposure to the HIV-1 nonnucleoside reverse transcriptase inhibitor nevirapine.
Therapeutic drug monitoring 2001;23(6):606-11.
2001: Wit F W; Wood R; Horban A; Beniowski M; Schmidt R E; Gray G; Lazzarin A; Lafeuillade A; Paes D; Carlier H; van Weert L; de Vries C; van Leeuwen R; Lange J M
Prednisolone does not prevent hypersensitivity reactions in antiretroviral drug regimens containing abacavir with or without nevirapine.
AIDS (London, England) 2001;15(18):2423-9.
2001: Rongkavilit C; Thaithumyanon P; Chuenyam T; Damle B D; Limpongsanurak S; Boonrod C; Srigritsanapol A; Hassink E A; Hoetelmans R M; Cooper D A; Lange J M; Ruxrungtham K; Phanuphak P
Pharmacokinetics of stavudine and didanosine coadministered with nelfinavir in human immunodeficiency virus-exposed neonates.
Antimicrobial agents and chemotherapy 2001;45(12):3585-90.
2001: Goudsmit J; Weverling G J; van der Hoek L; de Ronde A; Miedema F; Coutinho R A; Lange J M; Boerlijst M C
Carrier rate of zidovudine-resistant HIV-1: the impact of failing therapy on transmission of resistant strains.
AIDS (London, England) 2001;15(17):2293-301.
2001: van Rossum A M; Scherpbier H J; van Lochem E G; Pakker N G; Slieker W A; Wolthers K C; Roos M T; Kuijpers J H; Hooijkaas H; Hartwig N G; Geelen S P; Wolfs T F; Lange J M; Miedema F; de Groot R;
Therapeutic immune reconstitution in HIV-1-infected children is independent of their age and pretreatment immune status.
AIDS (London, England) 2001;15(17):2267-75.
2001: van der Valk M; Bisschop P H; Romijn J A; Ackermans M T; Lange J M; Endert E; Reiss P; Sauerwein H P
Lipodystrophy in HIV-1-positive patients is associated with insulin resistance in multiple metabolic pathways.
AIDS (London, England) 2001;15(16):2093-100.
2001: Nieuwkerk P T; Gisolf E H; Reijers M H; Lange J M; Danner S A; Sprangers M A;
Long-term quality of life outcomes in three antiretroviral treatment strategies for HIV-1 infection.
AIDS (London, England) 2001;15(15):1985-91.
2001: van Praag R M; van Heeswijk R P; Jurriaans S; Lange J M; Hoetelmans R M; Prins J M
Penetration of the nucleoside analogue abacavir into the genital tract of men infected with human immunodeficiency virus type 1.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2001;33(8):e91-2.
2001: van Praag R M; Repping S; de Vries J W; Lange J M; Hoetelmans R M; Prins J M
Pharmacokinetic profiles of nevirapine and indinavir in various fractions of seminal plasma.
Antimicrobial agents and chemotherapy 2001;45(10):2902-7.
2001: Nieuwkerk P T; Sprangers M A; Burger D M; Hoetelmans R M; Hugen P W; Danner S A; van Der Ende M E; Schneider M M; Schrey G; Meenhorst P L; Sprenger H G; Kauffmann R H; Jambroes M; Chesney M A; de Wolf F; Lange J M;
Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study.
Archives of internal medicine 2001;161(16):1962-8.
2001: Jambroes M; Weverling G J; Reiss P; Danner S A; Jurriaans S; ten Veen J H; van der Ende M E; Schutten M; Schneider M M; Schuurman R; Mulder J W; Kroes A C; Lange J M; de Wolf F;
[HIV-1 therapy in the Netherlands; virological and immunological response to antiretroviral therapy]
Nederlands tijdschrift voor geneeskunde 2001;145(33):1591-7.
2001: Veldkamp A I; van Heeswijk R P; Mulder J W; Meenhorst P L; Schreij G; van der Geest S; Lange J M; Beijnen J H; Hoetelmans R M
Steady-state pharmacokinetics of twice-daily dosing of saquinavir plus ritonavir in HIV-1-infected individuals.
Journal of acquired immune deficiency syndromes (1999) 2001;27(4):344-9.
2001: Veldkamp A I; Harris M; Montaner J S; Moyle G; Gazzard B; Youle M; Johnson M; Kwakkelstein M O; Carlier H; van Leeuwen R; Beijnen J H; Lange J M; Reiss P; Hoetelmans R M
The steady-state pharmacokinetics of efavirenz and nevirapine when used in combination in human immunodeficiency virus type 1-infected persons.
The Journal of infectious diseases 2001;184(1):37-42.
2001: Kostense S; Raaphorst F M; Joling J; Notermans D W; Prins J M; Danner S A; Reiss P; Lange J M; Teale J M; Miedema F
T cell expansions in lymph nodes and peripheral blood in HIV-1-infected individuals: effect of antiretroviral therapy.
AIDS (London, England) 2001;15(9):1097-107.
2001: Veldkamp A I; Weverling G J; Lange J M; Montaner J S; Reiss P; Cooper D A; Vella S; Hall D; Beijnen J H; Hoetelmans R M
High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals.
AIDS (London, England) 2001;15(9):1089-95.
2001: Ungsedhapand C; Kroon E D; Suwanagool S; Ruxrungtham K; Yimsuan N; Sonjai A; Ubolyam S; Buranapraditkun S; Tiengrim S; Pakker N; Kunanusont C; Lange J M; Cooper D A; Phanuphak P
A randomized, open-label, comparative trial of zidovudine plus lamivudine versus zidovudine plus lamivudine plus didanosine in antiretroviral-naive HIV-1-infected Thai patients.
Journal of acquired immune deficiency syndromes (1999) 2001;27(2):116-23.
2001: van Heeswijk R P; Veldkamp A I; Mulder J W; Meenhorst P L; Beijnen J H; Lange J M; Hoetelmans R M
Saliva as an alternative body fluid for therapeutic drug monitoring of the nonnucleoside reverse transcription inhibitor nevirapine.
Therapeutic drug monitoring 2001;23(3):255-8.
2001: van Praag R M; Prins J M; Roos M T; Schellekens P T; Ten Berge I J; Yong S L; Schuitemaker H; Eerenberg A J; Jurriaans S; de Wolf F; Fox C H; Goudsmit J; Miedema F; Lange J M
OKT3 and IL-2 treatment for purging of the latent HIV-1 reservoir in vivo results in selective long-lasting CD4+ T cell depletion.
Journal of clinical immunology 2001;21(3):218-26.
2001: Enting R H; Prins J M; Jurriaans S; Brinkman K; Portegies P; Lange J M
Concentrations of human immunodeficiency virus type 1 (HIV-1) RNA in cerebrospinal fluid after antiretroviral treatment initiated during primary HIV-1 infection.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2001;32(7):1095-9.
2001: Foudraine N A; Jurriaans S; Weverling G J; Burger D M; Hoetelmans R M; Roos M T; Maas J; Miedema F; Reiss P; Portegies P; de Wolf F; Lange J M
Durable HIV-1 suppression with indinavir after failing lamivudine-containing double nucleoside therapy: a randomized controlled trial.
Antiviral therapy 2001;6(1):55-62.
2001: Burger D M; Hugen P W; Aarnoutse R E; Dieleman J P; Prins J M; van der Poll T; ten Veen J H; Mulder J W; Meenhorst P L; Blok W L; van der Meer J T; Reiss P; Lange J M
A retrospective, cohort-based survey of patients using twice-daily indinavir + ritonavir combinations: pharmacokinetics, safety, and efficacy.
Journal of acquired immune deficiency syndromes (1999) 2001;26(3):218-24.
2001: Reijers M H; Weverling G J; Jurriaans S; Roos M T; Wit F W; Weigel H M; Ten Kate R W; Mulder J W; Richter C; Ter Hofstede H J; Sprenger H; Hoetelmans R M; Schuitemaker H; Lange J M
The ADAM study continued: maintenance therapy after 50 weeks of induction therapy.
AIDS (London, England) 2001;15(1):129-31.
2000: den Brinker M; Wit F W; Wertheim-van Dillen P M; Jurriaans S; Weel J; van Leeuwen R; Pakker N G; Reiss P; Danner S A; Weverling G J; Lange J M
Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection.
AIDS (London, England) 2000;14(18):2895-902.
2000: Putter H; Prins J M; Jurriaans S; Roos M; Ferguson N M; van Praag R; van der Hoek L; Schuitemaker H; Anderson R M; Goudsmit J; Lange J M; de Wolf F
Slower decline of plasma HIV-1 RNA following highly suppressive antiretroviral therapy in primary compared with chronic infection.
AIDS (London, England) 2000;14(18):2831-9.
2000: Gisolf E H; van Praag R M; Jurriaans S; Portegies P; Goudsmit J; Danner S A; Lange J M; Prins J M
Increasing cerebrospinal fluid chemokine concentrations despite undetectable cerebrospinal fluid HIV RNA in HIV-1-infected patients receiving antiretroviral therapy.
Journal of acquired immune deficiency syndromes (1999) 2000;25(5):426-33.
2000: Hugen P W; Burger D M; ter Hofstede H J; Koopmans P P; Stek M; Hekster Y A; Reiss P; Lange J M
Dose-finding study of a once-daily indinavir/ritonavir regimen.
Journal of acquired immune deficiency syndromes (1999) 2000;25(3):236-45.
2000: Burger D M; Hugen P W; van der Ende M E; van Wijngaarden P; Aarnoutse R E; Reiss P; Lange J M
Once-daily indinavir plus ritonavir: preliminary results of the PIPO study.
AIDS (London, England) 2000;14(16):2621-3.
2000: Notermans D W; de Wolf F; Oudshoorn P; Cuijpers H T; Pirillo M; Tiller F W; McClernon D R; Prins J M; Lange J M; Danner S A; Goudsmit J; Jurriaans S
Evaluation of a second-generation nucleic acid sequence-based amplification assay for quantification of HIV type 1 RNA and the use of ultrasensitive protocol adaptations.
AIDS research and human retroviruses 2000;16(15):1507-17.
2000: van Heeswijk R P; Veldkamp A I; Mulder J W; Meenhorst P L; Wit F W; Reiss P; Lange J M; Kwakkelstein M O; Beijnen J H; Hoetelmans R M
Nevirapine plus didanosine: once or twice daily combination?
Journal of acquired immune deficiency syndromes (1999) 2000;25(1):93-5.
2000: Hazenberg M D; Otto S A; Cohen Stuart J W; Verschuren M C; Borleffs J C; Boucher C A; Coutinho R A; Lange J M; Rinke de Wit T F; Tsegaye A; van Dongen J J; Hamann D; de Boer R J; Miedema F
Increased cell division but not thymic dysfunction rapidly affects the T-cell receptor excision circle content of the naive T cell population in HIV-1 infection.
Nature medicine 2000;6(9):1036-42.
2000: Ruxrungtham K; Kroon E D; Ungsedhapand C; Teeratakulpisarn S; Ubolyam S; Buranapraditkun S; van Leeuwen R; Weverling G J; Kunanusont C; Lange J M; Cooper D A; Phanuphak P
A randomized, dose-finding study with didanosine plus stavudine versus didanosine alone in antiviral-naive, HIV-infected Thai patients.
AIDS (London, England) 2000;14(10):1375-82.
2000: Kroon E D; Ungsedhapand C; Ruxrungtham K; Chuenyam M; Ubolyam S; Newell M E; van Leeuwen R; Kunanusont C; Buranapraditkul S; Sirivichayakul S; Lange J M; Cooper D A; Phanuphak P
A randomized, double-blind trial of half versus standard dose of zidovudine plus zalcitabine in Thai HIV-1-infected patients (study HIV-NAT 001). HIV Netherlands Australia Thailand Research Collaboration.
AIDS (London, England) 2000;14(10):1349-56.
2000: Clark D R; Repping S; Pakker N G; Prins J M; Notermans D W; Wit F W; Reiss P; Danner S A; Coutinho R A; Lange J M; Miedema F
T-cell progenitor function during progressive human immunodeficiency virus-1 infection and after antiretroviral therapy.
Blood 2000;96(1):242-9.
2000: Nieuwkerk P T; Reijers M H; Weigel H M; Lange J M; Sprangers M A
Quality of life in maintenance vs prolonged induction therapy for HIV.
JAMA : the journal of the American Medical Association 2000;284(2):178-9.
2000: van Praag R M; Weverling G J; Portegies P; Jurriaans S; Zhou X J; Turner-Foisy M L; Sommadossi J P; Burger D M; Lange J M; Hoetelmans R M; Prins J M
Enhanced penetration of indinavir in cerebrospinal fluid and semen after the addition of low-dose ritonavir.
AIDS (London, England) 2000;14(9):1187-94.
2000: van Heeswijk R P; Veldkamp A I; Mulder J W; Meenhorst P L; Lange J M; Beijnen J H; Hoetelmans R M
Once-daily dosing of saquinavir and low-dose ritonavir in HIV-1-infected individuals: a pharmacokinetic pilot study.
AIDS (London, England) 2000;14(9):F103-10.
2000: van Heeswijk R P; Veldkamp A I; Mulder J W; Meenhorst P L; Wit F W; Lange J M; Danner S A; Foudraine N A; Kwakkelstein M O; Reiss P; Beijnen J H; Hoetelmans R M
The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals.
AIDS (London, England) 2000;14(8):F77-82.
2000: Blank B S; Meenhorst P L; Mulder J W; Weverling G J; Putter H; Pauw W; van Dijk W C; Smits P; Lie-A-Ling S; Reiss P; Lange J M
Value of different assays for detection of human cytomegalovirus (HCMV) in predicting the development of HCMV disease in human immunodeficiency virus-infected patients.
Journal of clinical microbiology 2000;38(2):563-9.
2000: Reijers M H; Weigel H M; Hart A A; Ten Kate R W; Mulder J W; Reiss P; Schuitemaker H; Hoetelmans R M; Weverling G J; Lange J M
Toxicity and drug exposure in a quadruple drug regimen in HIV-1 infected patients participating in the ADAM study.
AIDS (London, England) 2000;14(1):59-67.
2000: Enting R H; Foudraine N A; Lange J M; Jurriaans S; van der Poll T; Weverling G J; Portegies P
Cerebrospinal fluid beta2-microglobulin, monocyte chemotactic protein-1, and soluble tumour necrosis factor alpha receptors before and after treatment with lamivudine plus zidovudine or stavudine.
Journal of neuroimmunology 2000;102(2):216-21.
1999: Blank B S; Meenhorst P L; Weverling G J; Stout-Zonneveld A A; Pauw W; Mulder J W; van Dijk W C; Smits P; Lange J M
Quantitative pp65-antigenemia assay for the prediction of human cytomegalovirus disease in HIV-infected patients.
AIDS (London, England) 1999;13(18):2533-9.
1999: Prins J M; Jurriaans S; van Praag R M; Blaak H; van Rij R; Schellekens P T; ten Berge I J; Yong S L; Fox C H; Roos M T; de Wolf F; Goudsmit J; Schuitemaker H; Lange J M
Immuno-activation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapy.
AIDS (London, England) 1999;13(17):2405-10.
1999: Veldkamp A I; van Heeswijk R P; Meenhorst P L; Mulder J W; Lange J M; Beijnen J H; Hoetelmans R M
Quantitative determination of efavirenz (DMP 266), a novel non-nucleoside reverse transcriptase inhibitor, in human plasma using isocratic reversed-phase high-performance liquid chromatography with ultraviolet detection.
Journal of chromatography. B, Biomedical sciences and applications 1999;734(1):55-61.
1999: van Heeswijk R P; Veldkamp A I; Hoetelmans R M; Mulder J W; Schreij G; Hsu A; Lange J M; Beijnen J H; Meenhorst P L
The steady-state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1-infected individuals.
AIDS (London, England) 1999;13(14):F95-9.
1999: van Rij R P; Portegies P; Hallaby T; Lange J M; Visser J; de Roda Husman A M; van 't Wout A B; Schuitemaker H
Reduced prevalence of the CCR5 delta32 heterozygous genotype in human immunodeficiency virus-infected individuals with AIDS dementia complex.
The Journal of infectious diseases 1999;180(3):854-7.
1999: Pontesilli O; Kerkhof-Garde S; Notermans D W; Foudraine N A; Roos M T; Klein M R; Danner S A; Lange J M; Miedema F
Functional T cell reconstitution and human immunodeficiency virus-1-specific cell-mediated immunity during highly active antiretroviral therapy.
The Journal of infectious diseases 1999;180(1):76-86.
1999: Brinkman K; Prins J M; Jurriaans S; Lange J M
[Primary HIV-infection: infectious mononucleosis-like presentation with treatment options]
Nederlands tijdschrift voor geneeskunde 1999;143(22):1129-33.
1999: Veldkamp A I; van Heeswijk R P; Hoetelmans R M; Meenhorst P L; Mulder J W; Lange J M; Beijnen J H
Rapid quantification of delavirdine, a novel non-nucleoside reverse transcriptase inhibitor, in human plasma using isocratic reversed-phase high-performance liquid chromatography with fluorescence detection.
Journal of chromatography. B, Biomedical sciences and applications 1999;727(1-2):151-7.
1999: Wit F W; van Leeuwen R; Weverling G J; Jurriaans S; Nauta K; Steingrover R; Schuijtemaker J; Eyssen X; Fortuin D; Weeda M; de Wolf F; Reiss P; Danner S A; Lange J M
Outcome and predictors of failure of highly active antiretroviral therapy: one-year follow-up of a cohort of human immunodeficiency virus type 1-infected persons.
The Journal of infectious diseases 1999;179(4):790-8.
1999: Pakker N G; Kroon E D; Roos M T; Otto S A; Hall D; Wit F W; Hamann D; van der Ende M E; Claessen F A; Kauffmann R H; Koopmans P P; Kroon F P; ten Napel C H; Sprenger H G; Weigel H M; Montaner J S; Lange J M; Reiss P; Schellekens P T; Miedema F
Immune restoration does not invariably occur following long-term HIV-1 suppression during antiretroviral therapy. INCAS Study Group.
AIDS (London, England) 1999;13(2):203-12.
1999: Foudraine N A; Hovenkamp E; Notermans D W; Meenhorst P L; Klein M R; Lange J M; Miedema F; Reiss P
Immunopathology as a result of highly active antiretroviral therapy in HIV-1-infected patients.
AIDS (London, England) 1999;13(2):177-84.
1999: Koot M; van Leeuwen R; de Goede R E; Keet I P; Danner S; Eeftinck Schattenkerk J K; Reiss P; Tersmette M; Lange J M; Schuitemaker H
Conversion rate towards a syncytium-inducing (SI) phenotype during different stages of human immunodeficiency virus type 1 infection and prognostic value of SI phenotype for survival after AIDS diagnosis.
The Journal of infectious diseases 1999;179(1):254-8.
1998: Dieleman J P; Hillebrand-Haverkort M E; van der Ende M E; Sturkenboom M C; Lange J M; Stricker B H
[Lipodystrophy and 'buffalo hump' during treatment with HIV protease inhibitors]
Nederlands tijdschrift voor geneeskunde 1998;142(52):2856-60.
1998: Renwick N; Halaby T; Weverling G J; Dukers N H; Simpson G R; Coutinho R A; Lange J M; Schulz T F; Goudsmit J
Seroconversion for human herpesvirus 8 during HIV infection is highly predictive of Kaposi's sarcoma.
AIDS (London, England) 1998;12(18):2481-8.
1998: Hoetelmans R M; van Heeswijk R P; Profijt M; Mulder J W; Meenhorst P L; Lange J M; Reiss P; Beijnen J H
Comparison of the plasma pharmacokinetics and renal clearance of didanosine during once and twice daily dosing in HIV-1 infected individuals.
AIDS (London, England) 1998;12(17):F211-6.
1998: van Heeswijk R P; Hoetelmans R M; Harms R; Meenhorst P L; Mulder J W; Lange J M; Beijnen J H
Simultaneous quantitative determination of the HIV protease inhibitors amprenavir, indinavir, nelfinavir, ritonavir and saquinavir in human plasma by ion-pair high-performance liquid chromatography with ultraviolet detection.
Journal of chromatography. B, Biomedical sciences and applications 1998;719(1-2):159-68.
1998: Reijers M H; Weverling G J; Jurriaans S; Wit F W; van Leeuwen R; Bruisten S M; Frissen P H; Weigel H M; Mulder J W; ten Kate R W; de Wolf F; Schuitemaker H; Lange J M
[Amsterdam duration of antiretroviral medication (ADAM)--study: induction-suppression treatment in HIV-I infection, preliminary results]
Nederlands tijdschrift voor geneeskunde 1998;142(40):2230.
1998: Enting R H; Hoetelmans R M; Lange J M; Burger D M; Beijnen J H; Portegies P
Antiretroviral drugs and the central nervous system.
AIDS (London, England) 1998;12(15):1941-55.
1998: Foudraine N A; de Jong J J; Jan Weverling G; van Benthem B H; Maas J; Keet I P; Jurriaans S; Roos M T; Vandermeulen K; de Wolf F; Lange J M
An open randomized controlled trial of zidovudine plus lamivudine versus stavudine plus lamivudine.
AIDS (London, England) 1998;12(12):1513-9.
1998: Weverling G J; Lange J M; Jurriaans S; Prins J M; Lukashov V V; Notermans D W; Roos M; Schuitemaker H; Hoetelmans R M; Danner S A; Goudsmit J; de Wolf F
Alternative multidrug regimen provides improved suppression of HIV-1 replication over triple therapy.
AIDS (London, England) 1998;12(11):F117-22.
1998: Hoetelmans R M; Reijers M H; Weverling G J; ten Kate R W; Wit F W; Mulder J W; Weigel H M; Frissen P H; Roos M; Jurriaans S; Schuitemaker H; de Wolf F; Beijnen J H; Lange J M
The effect of plasma drug concentrations on HIV-1 clearance rate during quadruple drug therapy.
AIDS (London, England) 1998;12(11):F111-5.
1998: Reijers M H; Weverling G J; Jurriaans S; Wit F W; Weigel H M; Ten Kate R W; Mulder J W; Frissen P H; van Leeuwen R; Reiss P; Schuitemaker H; de Wolf F; Lange J M
Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: Amsterdam Duration of Antiretroviral Medication (ADAM) study.
Lancet 1998;352(9123):185-90.
1998: Foudraine N A; Hoetelmans R M; Lange J M; de Wolf F; van Benthem B H; Maas J J; Keet I P; Portegies P
Cerebrospinal-fluid HIV-1 RNA and drug concentrations after treatment with lamivudine plus zidovudine or stavudine.
Lancet 1998;351(9115):1547-51.
1998: de Wolf F; de Jong J J; Hertogs K; Danner S A; Lange J M; Goudsmit J
[Virological evaluation of treating HIV-infected patients with (combinations of) antiretroviral drugs at the Amsterdam Academic Medical Center, 1996/'97]
Nederlands tijdschrift voor geneeskunde 1998;142(11):573-8.
1998: Foudraine N A; Weverling G J; van Gool T; Roos M T; de Wolf F; Koopmans P P; van den Broek P J; Meenhorst P L; van Leeuwen R; Lange J M; Reiss P
Improvement of chronic diarrhoea in patients with advanced HIV-1 infection during potent antiretroviral therapy.
AIDS (London, England) 1998;12(1):35-41.
1998: Lange J M
Strategies for rescue therapy.
Antiviral therapy 1998;3 Suppl 4():75-7.
1998: Phanuphak P; Cooper D A; Lange J M
Clinical trials in Asia.
AIDS (London, England) 1998;12 Suppl B():S163-7.
1997: Pakker N G; Roos M T; van Leeuwen R; de Jong M D; Koot M; Reiss P; Lange J M; Miedema F; Danner S A; Schellekens P T
Patterns of T-cell repopulation, virus load reduction, and restoration of T-cell function in HIV-infected persons during therapy with different antiretroviral agents.
Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association 1997;16(5):318-26.
1997: van't Wout A B; Ran L J; de Jong M D; Bakker M; van Leeuwen R; Notermans D W; Loeliger A E; de Wolf F; Danner S A; Reiss P; Boucher C A; Lange J M; Schuitemaker H
Selective inhibition of syncytium-inducing and nonsyncytium-inducing HIV-1 variants in individuals receiving didanosine or zidovudine, respectively.
The Journal of clinical investigation 1997;100(9):2325-32.
1997: de Jong M D; de Boer R J; de Wolf F; Foudraine N A; Boucher C A; Goudsmit J; Lange J M
Overshoot of HIV-1 viraemia after early discontinuation of antiretroviral treatment.
AIDS (London, England) 1997;11(11):F79-84.
1997: Frissen P H; de Wolf F; Reiss P; Bakker P J; Veenhof C H; Danner S A; Goudsmit J; Lange J M
High-dose interferon-alpha2a exerts potent activity against human immunodeficiency virus type 1 not associated with antitumor activity in subjects with Kaposi's sarcoma.
The Journal of infectious diseases 1997;176(3):811-4.
1997: van Leeuwen R; Bonsel G J; Reiss P; Danner S A; Lange J M
Additive or sequential nucleoside analogue therapy compared with continued zidovudine monotherapy in human immunodeficiency virus-infected patients with advanced disease does not prolong survival: an observational study.
The Journal of infectious diseases 1997;175(6):1344-51.
1997: Veenstra J; Veugelers P J; Keet I P; van der Ven A J; Miedema F; Lange J M; Coutinho R A
Rapid disease progression in human immunodeficiency virus type 1-infected individuals with adverse reactions to trimethoprim-sulfamethoxazole prophylaxis.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1997;24(5):936-41.
1997: van Leeuwen R; Lange J M; Nijhuis M; Schuurman R; Reiss P; Danner S A; Boucher C A
Results of long-term follow-up of HIV-infected patients treated with lamivudine monotherapy, followed by a combination of lamivudine and zidovudine.
Antiviral therapy 1997;2(2):79-90.
1997: Lange J M
Current problems and the future of antiretroviral drug trials.
Science (New York, N.Y.) 1997;276(5312):548-50.
1997: de Jong M D; Vella S; Carr A; Boucher C A; Imrie A; French M; Hoy J; Sorice S; Pauluzzi S; Chiodo F; Weverling G J; van der Ende M E; Frissen P J; Weigel H M; Kauffmann R H; Lange J M; Yoon R; Moroni M; Hoenderdos E; Leitz G; Cooper D A; Hall D; Reiss P
High-dose nevirapine in previously untreated human immunodeficiency virus type 1-infected persons does not result in sustained suppression of viral replication.
The Journal of infectious diseases 1997;175(4):966-70.
1996: Weverling G J; Lange J M; de Jong M D; de Weerd H; Goudsmit J; de Wolf F
A comparison of serum HIV-1 RNA levels as measured by two quantitative assays in zidovudine-treated, asymptomatic, HIV-infected individuals.
Antiviral therapy 1996;1(4):255-63.
1996: van 't Wout A B; de Jong M D; Kootstra N A; Veenstra J; Lange J M; Boucher C A; Schuitemaker H
Changes in cellular virus load and zidovudine resistance of syncytium-inducing and non-syncytium-inducing human immunodeficiency virus populations under zidovudine pressure: a clonal analysis.
The Journal of infectious diseases 1996;174(4):845-9.
1996: Notermans D W; van Leeuwen R; Lange J M
Treatment of HIV infection. Tolerability of commonly used antiretroviral agents.
Drug safety : an international journal of medical toxicology and drug experience 1996;15(3):176-87.
1996: Roos M T; Miedema F; Meinesz A P; De Leeuw N A; Pakker N G; Lange J M; Coutinho R A; Schellekens P T
Low T cell reactivity to combined CD3 plus CD28 stimulation is predictive for progression to AIDS: correlation with decreased CD28 expression.
Clinical and experimental immunology 1996;105(3):409-15.
1996: Frissen P H; Weverling G J; Endert E; Jansen J; Sauerwein H P; Lange J M
Predictive value for survival of soluble tumor necrosis factor receptors p55 and p75 during zidovudine-containing treatment in symptomatic human immunodeficiency virus type 1 infection.
Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association 1996;12(5):482-8.
1996: De Boer J B; Sprangers M A; Aaronson N K; Lange J M; van Dam F S
A study of the reliability, validity and responsiveness of the HIV overview of problems evaluation system (HOPES) in assessing the quality of life of patients with AIDS and symptomatic HIV infection.
Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation 1996;5(3):339-47.
1996: de Jong M D; Veenstra J; Stilianakis N I; Schuurman R; Lange J M; de Boer R J; Boucher C A
Host-parasite dynamics and outgrowth of virus containing a single K70R amino acid change in reverse transcriptase are responsible for the loss of human immunodeficiency virus type 1 RNA load suppression by zidovudine.
Proceedings of the National Academy of Sciences of the United States of America 1996;93(11):5501-6.
1996: Frissen P H; Brinkman K; Ten Napel C H; van der Ende I M; van Buuren I A; Boucher C A; Reiss P; Lange J M
Tolerability and activity of a new recombinant interferon-alpha B/D hybrid in patients with HIV-1 infection.
Antiviral therapy 1996;1(2):89-97.
1996: Veenstra J; van Praag R M; Krol A; Wertheim van Dillen P M; Weigel H M; Schellekens P T; Lange J M; Coutinho R A; van der Meer J T
Complications of varicella zoster virus reactivation in HIV-infected homosexual men.
AIDS (London, England) 1996;10(4):393-9.
1996: de Jong M D; Schuurman R; Lange J M; Boucher C A
Replication of a pre-existing resistant HIV-1 subpopulation in vivo after introduction of a strong selective drug pressure.
Antiviral therapy 1996;1(1):33-41.
1996: de Jong M D; Boucher C A; Galasso G J; Hirsch M S; Kern E R; Lange J M; Richman D D
Consensus symposium on combined antiviral therapy. International Society for Antiviral Research and the National Institutes of Allergy and Infectious Diseases.
Antiviral research 1996;29(1):5-29.
1995: Godfried M H; van der Poll T; Mulder J W; Weverling G J; Endert E; Lange J M; Sauerwein H P
Soluble tumor necrosis factor receptors as surrogate markers for the assessment of zidovudine treatment in asymptomatic HIV-1 infection.
Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association 1995;10(5):531-9.
1995: Veenstra J; Krol A; van Praag R M; Frissen P H; Schellekens P T; Lange J M; Coutinho R A; van der Meer J T
Herpes zoster, immunological deterioration and disease progression in HIV-1 infection.
AIDS (London, England) 1995;9(10):1153-8.
1994: Portegies P; Enting R H; de Jong M D; Danner S A; Reiss P; Goudsmit J; Lange J M
AIDS dementia complex and didanosine.
Lancet 1994;344(8924):759.
1993: Koot M; Schellekens P T; Mulder J W; Lange J M; Roos M T; Coutinho R A; Tersmette M; Miedema F
Viral phenotype and T cell reactivity in human immunodeficiency virus type 1-infected asymptomatic men treated with zidovudine.
The Journal of infectious diseases 1993;168(3):733-6.
1993: de Boer J B; van Dam F S; Sprangers M A; Frissen P H; Lange J M
Longitudinal study on the Quality of Life of symptomatic HIV-infected patients in a trial of zidovudine versus zidovudine and interferon-alpha.
AIDS (London, England) 1993;7(7):947-53.
1993: Boucher C A; van Leeuwen R; Kellam P; Schipper P; Tijnagel J; Lange J M; Larder B A
Effects of discontinuation of zidovudine treatment on zidovudine sensitivity of human immunodeficiency virus type 1 isolates.
Antimicrobial agents and chemotherapy 1993;37(7):1525-30.
1993: Portegies P; Enting R H; de Gans J; Algra P R; Derix M M; Lange J M; Goudsmit J
Presentation and course of AIDS dementia complex: 10 years of follow-up in Amsterdam, The Netherlands.
AIDS (London, England) 1993;7(5):669-75.
1993: Lange J M; Teeuwsen V J; Boucher C A; Vahlne A; Barin F; Tjong-A-Hung S; Dekker J; Parkhede U; de Wolf F; Goudsmit J
Antigenic variation of the dominant gp41 epitope in Africa.
AIDS (London, England) 1993;7(4):461-6.
1993: Keet I P; Krijnen P; Koot M; Lange J M; Miedema F; Goudsmit J; Coutinho R A
Predictors of rapid progression to AIDS in HIV-1 seroconverters.
AIDS (London, England) 1993;7(1):51-7.
1993: Lange J M; de Jong M D
The clinical significance of the biological phenotype of HIV.
AIDS clinical review 1993;():1-18.
1992: van Leeuwen R; Lange J M; Hussey E K; Donn K H; Hall S T; Harker A J; Jonker P; Danner S A
The safety and pharmacokinetics of a reverse transcriptase inhibitor, 3TC, in patients with HIV infection: a phase I study.
AIDS (London, England) 1992;6(12):1471-5.
1992: Boucher C A; Lange J M; Miedema F F; Weverling G J; Koot M; Mulder J W; Goudsmit J; Kellam P; Larder B A; Tersmette M
HIV-1 biological phenotype and the development of zidovudine resistance in relation to disease progression in asymptomatic individuals during treatment.
AIDS (London, England) 1992;6(11):1259-64.
1992: Schuitemaker H; Koot M; Kootstra N A; Dercksen M W; de Goede R E; van Steenwijk R P; Lange J M; Schattenkerk J K; Miedema F; Tersmette M
Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population.
Journal of virology 1992;66(3):1354-60.
1992: Enting R H; Portegies P; Algra P R; Valk J; Lange J M
[Progressive multifocal leukoencephalopathy in AIDS]
Nederlands tijdschrift voor geneeskunde 1992;136(11):521-6.
1992: Roos M T; Lange J M; de Goede R E; Coutinho R A; Schellekens P T; Miedema F; Tersmette M
Viral phenotype and immune response in primary human immunodeficiency virus type 1 infection.
The Journal of infectious diseases 1992;165(3):427-32.
1992: Mulder J W; Frissen P H; Krijnen P; Endert E; de Wolf F; Goudsmit J; Masterson J G; Lange J M
Dehydroepiandrosterone as predictor for progression to AIDS in asymptomatic human immunodeficiency virus-infected men.
The Journal of infectious diseases 1992;165(3):413-8.
1992: Boucher C A; O'Sullivan E; Mulder J W; Ramautarsing C; Kellam P; Darby G; Lange J M; Goudsmit J; Larder B A
Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects.
The Journal of infectious diseases 1992;165(1):105-10.
1992: de Gans J; Portegies P; Reiss P; Troost D; van Gool T; Lange J M
Pyrimethamine alone as maintenance therapy for central nervous system toxoplasmosis in 38 patients with AIDS.
Journal of acquired immune deficiency syndromes 1992;5(2):137-42.
1991: de Jong M D; Hulsebosch H J; Lange J M
Clinical, virological and immunological features of primary HIV-1 infection.
Genitourinary medicine 1991;67(5):367-73.
1991: Teeuwsen V J; Lange J M; Keet R; Schattenkerk J K; Debouck C; van den Akker R; Goudsmit J; Osterhaus A D
Low number of functionally active B lymphocytes in the peripheral blood of HIV-1-seropositive individuals with low p24-specific serum antibody titers.
AIDS (London, England) 1991;5(8):971-9.
1991: van der Wouw P A; van Leeuwen R; van Oers R H; Lange J M; Danner S A
Effects of recombinant human granulocyte colony-stimulating factor on leucopenia in zidovudine-treated patients with AIDS and AIDS related complex, a phase I/II study.
British journal of haematology 1991;78(3):319-24.
1991: Mulder J W; Krijnen P; Coutinho R A; Bakker M; Goudsmit J; Lange J M
Serum beta 2-microglobulin levels in asymptomatic HIV-1-infected subjects during long-term zidovudine treatment.
Genitourinary medicine 1991;67(3):188-93.
1991: de Jong M D; Lange J M; Smits N J; Reiss P
[Pneumocystis carinii infection during prophylaxis with nebulized pentamidine in a patient with AIDS]
Nederlands tijdschrift voor geneeskunde 1991;135(10):424-7.
1991: Portegies P; Algra P R; Hollak C E; Prins J M; Reiss P; Valk J; Lange J M
Response to cytarabine in progressive multifocal leucoencephalopathy in AIDS.
Lancet 1991;337(8742):680-1.
1991: de Wit R; Danner S A; Bakker P J; Lange J M; Eeftinck Schattenkerk J K; Veenhof C H
Combined zidovudine and interferon-alpha treatment in patients with AIDS-associated Kaposi's sarcoma.
Journal of internal medicine 1991;229(1):35-40.
1991: de Wolf F; Lange J M
Serologic and immunologic markers in the course of HIV-1 infection.
Clinics in dermatology 1991;9(1):1-11.
1991: Gruters R A; Terpstra F G; Lange J M; Roos M T; Harkema T; Mulder J W; De Wolf F; Schellekens P T; Miedema F
Differences in clinical course in zidovudine-treated asymptomatic HIV-infected men associated with T-cell function at intake.
AIDS (London, England) 1991;5(1):43-7.
1991: Lange J M; Cooper D A; Danner S A
Antiretroviral treatment: state of the art and future directions.
AIDS (London, England) 1991;5 Suppl 2():S181-8.
1990: van Leeuwen R; van den Hurk P J; Jöbsis G J; van der Wouw P A; Reiss P; Eeftinck Schattenkerk J K; Danner S A; Lange J M
Failure to maintain high-dose treatment regimens during long-term use of zidovudine in patients with symptomatic human immunodeficiency virus type 1 infection.
Genitourinary medicine 1990;66(6):418-22.
1990: Keet I P; Lee F K; van Griensven G J; Lange J M; Nahmias A; Coutinho R A
Herpes simplex virus type 2 and other genital ulcerative infections as a risk factor for HIV-1 acquisition.
Genitourinary medicine 1990;66(5):330-3.
1990: Hulsebosch H J; Claessen F A; van Ginkel C J; Kuiters G R; Goudsmit J; Lange J M
Human immunodeficiency virus exanthem.
Journal of the American Academy of Dermatology 1990;23(3 Pt 1):483-6.
1990: Boucher C A; Tersmette M; Lange J M; Kellam P; de Goede R E; Mulder J W; Darby G; Goudsmit J; Larder B A
Zidovudine sensitivity of human immunodeficiency viruses from high-risk, symptom-free individuals during therapy.
Lancet 1990;336(8715):585-90.
1990: Hollak C E; Kersten M J; van der Lelie J; Lange J M
Thrombocytopenic purpura as first manifestation of human immunodeficiency virus type I (HIV-1) infection.
The Netherlands journal of medicine 1990;37(1-2):63-8.
1990: Mulder J W; Lange J M; de Wolf F; Houweling J T; Bakker M; Coutinho R A; Goudsmit J
Serum p24 antigen levels in untreated and zidovudine-treated HIV-1 infected subjects.
The Netherlands journal of medicine 1990;37(1-2):4-10.
1990: Mulder J W; Krijnen P; Goudsmit J; Schattenkerk J K; Reiss P; Lange J M
HIV-1 P24 antigenaemia does not predict time of survival in AIDS patients.
Genitourinary medicine 1990;66(3):138-41.
1990: Eeftinck Schattenkerk J K; Lange J M; van Steenwijk R P; Danner S A
Can the course of high dose cotrimoxazole for Pneumocystis carinii pneumonia in AIDS be shorter? A possible solution to the problem of cotrimoxazole toxicity.
Journal of internal medicine 1990;227(5):359-62.
1990: Lange J M; Boucher C A; Hollak C E; Wiltink E H; Reiss P; van Royen E A; Roos M; Danner S A; Goudsmit J
Failure of zidovudine prophylaxis after accidental exposure to HIV-1.
The New England journal of medicine 1990;322(19):1375-7.
1990: de Wit R; Bakker P J; Reiss P; Hoek F J; Lange J M; Goudsmit J; Veenhof K H
Temporary increase in serum beta 2-microglobulin during treatment with interferon-alpha for AIDS-associated Kaposi's sarcoma.
AIDS (London, England) 1990;4(5):459-62.
1990: de Gans J; Portegies P; Tiessens G; Troost D; Danner S A; Lange J M
Therapy for cytomegalovirus polyradiculomyelitis in patients with AIDS: treatment with ganciclovir.
AIDS (London, England) 1990;4(5):421-5.
1990: Reiss P; Lange J M; de Ronde A; de Wolf F; Dekker J; Debouck C; Goudsmit J
Speed of progression to AIDS and degree of antibody response to accessory gene products of HIV-1.
Journal of medical virology 1990;30(3):163-8.
1990: Schellekens P T; Roos M T; De Wolf F; Lange J M; Miedema F
Low T-cell responsiveness to activation via CD3/TCR is a prognostic marker for acquired immunodeficiency syndrome (AIDS) in human immunodeficiency virus-1 (HIV-1)-infected men.
Journal of clinical immunology 1990;10(2):121-7.
1990: Mulder J W; de Wolf F; Goudsmit J; Cload P A; Coutinho R A; Fiddian A P; Schellekens P T; van der Noordaa J; Lange J M
Long-term zidovudine treatment of asymptomatic HIV-1-infected subjects.
Antiviral research 1990;13(3):127-38.
1990: Van Der Pijl J W; Frissen P H; Reiss P; Hulsebosch H J; Van Den Tweel J G; Lange J M; Danner S A
Foscarnet and penile ulceration.
Lancet 1990;335(8684):286.
1990: Reiss P; Lange J M; de Ronde A; de Wolf F; Dekker J; Danner S A; Debouck C; Goudsmit J
Antibody response to viral proteins U (vpu) and R (vpr) in HIV-1-infected individuals.
Journal of acquired immune deficiency syndromes 1990;3(2):115-22.
1989: de Wit R; Reiss P; Bakker P J; Lange J M; Danner S A; Veenhof K H
Lack of activity of zidovudine in AIDS-associated Kaposi's sarcoma.
AIDS (London, England) 1989;3(12):847-50.
1989: van der Wouw P A; Hadderingh R J; Reiss P; Hulsebosch H J; Walford N; Lange J M
Disseminated cat-scratch disease in a patient with AIDS.
AIDS (London, England) 1989;3(11):751-3.
1989: de Wolf F; Lange J M; Houweling J T; Mulder J W; Beemster J; Schellekens P T; Coutinho R A; van der Noordaa J; Goudsmit J
Appearance of predictors of disease progression in relation to the development of AIDS.
AIDS (London, England) 1989;3(9):563-9.
1989: Portegies P; de Gans J; Lange J M; Derix M M; Speelman H; Bakker M; Danner S A; Goudsmit J
Declining incidence of AIDS dementia complex after introduction of zidovudine treatment.
BMJ (Clinical research ed.) 1989;299(6703):819-21.
1989: Tersmette M; Lange J M; de Goede R E; de Wolf F; Eeftink-Schattenkerk J K; Schellekens P T; Coutinho R A; Huisman J G; Goudsmit J; Miedema F
Association between biological properties of human immunodeficiency virus variants and risk for AIDS and AIDS mortality.
Lancet 1989;1(8645):983-5.
1989: Tersmette M; Gruters R A; de Wolf F; de Goede R E; Lange J M; Schellekens P T; Goudsmit J; Huisman H G; Miedema F
Evidence for a role of virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired immunodeficiency syndrome: studies on sequential HIV isolates.
Journal of virology 1989;63(5):2118-25.
1989: Reiss P; de Ronde A; Lange J M; de Wolf F; Dekker J; Debouck C; Goudsmit J
Antibody response to the viral negative factor (nef) in HIV-1 infection: a correlate of levels of HIV-1 expression.
AIDS (London, England) 1989;3(4):227-33.
1989: Lange J M; de Wolf F; Mulder J W; Coutinho R A; van der Noordaa J; Goudsmit J
Markers for progression to acquired immune deficiency syndrome and zidovudine treatment of asymptomatic patients.
The Journal of infection 1989;18 Suppl 1():85-91.
1989: Lange J M; de Wolf F; Goudsmit J
Markers for progression in HIV infection.
AIDS (London, England) 1989;3 Suppl 1():S153-60.
1988: Miedema F; Petit A J; Terpstra F G; Schattenkerk J K; de Wolf F; Al B J; Roos M; Lange J M; Danner S A; Goudsmit J
Immunological abnormalities in human immunodeficiency virus (HIV)-infected asymptomatic homosexual men. HIV affects the immune system before CD4+ T helper cell depletion occurs.
The Journal of clinical investigation 1988;82(6):1908-14.
1988: De Wolf F; Roos M; Lange J M; Houweling J T; Coutinho R A; van der Noordaa J; Schellekens P T; Goudsmit J
Decline in CD4+ cell numbers reflects increase in HIV-1 replication.
AIDS research and human retroviruses 1988;4(6):433-40.
1988: de Wolf F; Lange J M; Houweling J T; Coutinho R A; Schellekens P T; van der Noordaa J; Goudsmit J
Numbers of CD4+ cells and the levels of core antigens of and antibodies to the human immunodeficiency virus as predictors of AIDS among seropositive homosexual men.
The Journal of infectious diseases 1988;158(3):615-22.
1988: de Gans J; Lange J M; Derix M M; de Wolf F; Ongerboer de Visser B W; Goudsmit J
[Decrease in human immunodeficiency virus antigen levels in the cerebrospinal fluid during zidovudine treatment in patients with AIDS]
Nederlands tijdschrift voor geneeskunde 1988;132(36):1656-60.
1988: Bakker P J; Danner S A; Lange J M; Veenhof K H
Etoposide for epidemic Kaposi's sarcoma: a phase II study.
European journal of cancer & clinical oncology 1988;24(6):1047-8.
1988: de Gans J; Lange J M; Derix M M; de Wolf F; Eeftinck Schattenkerk J K; Danner S A; Ongerboer de Visser B W; Cload P; Goudsmit J
Decline of HIV antigen levels in cerebrospinal fluid during treatment with low-dose zidovudine.
AIDS (London, England) 1988;2(1):37-40.
1988: Lange J M; Parry J V; de Wolf F; Mortimer P P; Goudsmit J
Diagnostic value of specific IgM antibodies in primary HIV infection.
AIDS (London, England) 1988;2(1):31-5.
1988: de Wolf F; Lange J M; Goudsmit J; Cload P; de Gans J; Schellekens P T; Coutinho R A; Fiddian A P; van der Noordaa J
Effect of zidovudine on serum human immunodeficiency virus antigen levels in symptom-free subjects.
Lancet 1988;1(8582):373-6.
1988: Tersmette M; Lelie P N; van der Poel C L; Wester M R; de Goede R E; Lange J M; Miedema F; Huisman J G
Confirmation of HIV seropositivity: comparison of a novel radioimmunoprecipitation assay to immunoblotting and virus culture.
Journal of medical virology 1988;24(1):109-16.
1988: Eeftinck Schattenkerk J K; Danner S A; Lange J M; Paul D A; van Boxtel C J; Miedema F; Schellekens P T; Goudsmit J
Persistence of human immunodeficiency virus antigenemia in patients with the acquired immunodeficiency syndrome treated with a reverse transcriptase inhibitor, suramin. Ten-patient case-control study.
Archives of internal medicine 1988;148(1):209-11.
1988: Goudsmit J; Lange J M; Smit L; Bakker M; Klaver B; Danner S A; Coutinho R A
Serodiagnostic profiles of HIV and HIV pathogenesis in vivo.
Haematologia 1988;21(2):71-81.
1987: van der Lelie J; Lange J M; Vos J J; van Dalen C M; Danner S A; von dem Borne A E
Autoimmunity against blood cells in human immunodeficiency-virus (HIV) infection.
British journal of haematology 1987;67(1):109-14.
1987: Lange J M; de Wolf F; Krone W J; Danner S A; Coutinho R A; Goudsmit J
Decline of antibody reactivity to outer viral core protein p17 is an earlier serological marker of disease progression in human immunodeficiency virus infection than anti-p24 decline.
AIDS (London, England) 1987;1(3):155-9.
1987: de Wolf F; Goudsmit J; Paul D A; Lange J M; Hooijkaas C; Schellekens P; Coutinho R A; van der Noordaa J
Risk of AIDS related complex and AIDS in homosexual men with persistent HIV antigenaemia.
British medical journal (Clinical research ed.) 1987;295(6598):569-72.
1987: Danner S A; Eeftinck Schattenkerk J K; Lange J M; van Steenwijk R P; de Gans J; Menardi T R;
[Disease symptoms and clinical course in the first 100 patients with AIDS]
Nederlands tijdschrift voor geneeskunde 1987;131(34):1474-81.
1987: Goudsmit J; Lange J M; Krone W J; Teunissen M B; Epstein L G; Danner S A; van den Berg H; Breederveld C; Smit L; Bakker M
Pathogenesis of HIV and its implications for serodiagnosis and monitoring of antiviral therapy.
Journal of virological methods 1987;17(1-2):19-34.
1987: Lange J M; Paul D A; de Wolf F; Coutinho R A; Goudsmit J
Viral gene expression, antibody production and immune complex formation in human immunodeficiency virus infection.
AIDS (London, England) 1987;1(1):15-20.
1986: Lange J M; Paul D A; Huisman H G; de Wolf F; van den Berg H; Coutinho R A; Danner S A; van der Noordaa J; Goudsmit J
Persistent HIV antigenaemia and decline of HIV core antibodies associated with transition to AIDS.
British medical journal (Clinical research ed.) 1986;293(6560):1459-62.
1986: Goudsmit J; de Wolf F; Paul D A; Epstein L G; Lange J M; Krone W J; Speelman H; Wolters E C; Van der Noordaa J; Oleske J M
Expression of human immunodeficiency virus antigen (HIV-Ag) in serum and cerebrospinal fluid during acute and chronic infection.
Lancet 1986;2(8500):177-80.

Sign-in to see more